GSK3511294

DRUG3 trials

Sponsors

Glaxosmithkline Research & Development Limited, GlaxoSmithKline

Conditions

AsthmaSevere asthma with an eosinophilic phenotype

Phase 1

First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma

CompletedNCT03287310

GlaxoSmithKlineAsthma

Start: 2017-10-17End: 2019-07-31Updated: 2021-03-01

Phase 3

A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

CompletedNCT04718103

GlaxoSmithKlineAsthma

Start: 2021-02-04End: 2024-04-11Updated: 2024-11-29

A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 (depemokimab) compared with mepolizumab or benralizumab

CompletedCTIS2023-510230-84-00

Glaxosmithkline Research & Development LimitedSevere asthma with an eosinophilic phenotype

Start: 2021-05-28End: 2025-09-10Target: 750Updated: 2025-10-27

Related Papers

Depemokimab demonstrates efficacy in patients with type 2 asthma with comorbid CRSwNP: Phase III SWIFT-1/-2 analysis

Frontiers in Allergy2026-03-06

Safety and Tolerability of Twice-Yearly Depemokimab in Patients with Asthma and Chronic Rhinosinusitis with Nasal Polyps: Pooled Results from SWIFT-1/-2 and ANCHOR-1/-2.

2025-12-29

Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype

New England Journal of Medicine2024-09-0978 citations

Phase 1 study of a novel, prolonged-action anti-IL-5 monoclonal antibody in asthma

2021-09-05

A Phase 1 study of the long‐acting anti‐IL‐5 monoclonal antibody GSK3511294 in patients with asthma

British Journal of Clinical Pharmacology2021-07-2250 citations